Sunday 11 October 2026 Export all JNJ data to Excel Powerpack

Johnson & Johnson

JNJ Healthcare Drug Manufacturers General

Johnson & Johnson’s revenue for fiscal 2025 (year ended December 2025) was $94.2 billion, up 6.05% from fiscal 2024. In the quarter to June 2026, revenue grew 6.60%, EPS was flat, free cash flow grew 154.8% and total debt fell 4.82%, each against the same quarter a year earlier. Member of the S&P 500 and Dow Jones; dividend growth for twenty-five consecutive years, revenue growth for three, operating cash flow growth for three; insiders bought in the last twelve months.

261.44 4.96 +1.93%
Market cap
$618.1B
P/E
30.3×
Fwd P/E
24.9×
Dividend yield
2.02%
F-score
3/9
Altman Z
4.78
Beneish M
−2.26
Dividend safety
78/100

Johnson & Johnson 10-Q filed Jul 23, 2026

Fiscal Q2 2026 · Period ended Jun 28, 2026 · Filed · accepted 4:04 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Apr 22, 2026: 48 added · 13 removed · 34 modified; 14 with only figures updated; 5 moved without change

  1. Added · Analysis of consolidated sales

    For the fiscal six months of 2026, worldwide sales were $49.4 billion, a total increase of 8.2%, including an operational* increase of 6.0% as compared to 2025 fiscal six months sales of $45.6 billion. Currency fluctuations had a positive impact of 2.2% for the fiscal six months of 2026. In the fiscal six months of 2026, acquisitions and divestitures had net positive impact of 0.5%, on worldwide operational sales growth, primarily related to CAPLYTA. In the fiscal six months of 2026, the negative impact of the STELARA sales decline, due to biosimilar competition, on worldwide operational sales was approximately 5.0%.

94 more changes in this Item, word by word, in Powerpack.

Powerpack